Thanks Sukus. Yes, I don't want to totally say Optune is not potentially helpful. If some doctors and patients want it, they should be able to have it.
But clearly it is not what some people are suggesting and it probably is misunderstood by many patients as well. And it is extremely expensive for what it offers.
Plus, we don't exactly know, given all the posts around here, which patients get to "5 years" if any, in reality. But assuming some do, they may have benefitted from other treatments and been the best of the best.
But most patients are going to have remaining tumor tissue and probably the best have virtually none, which mans they might have done well anyway. Additionally, I believe their trial did not use the new definition of GBM (IDH-Wild Type), so that 5% or a large percentage of it may have been now defined NOT as GBM because they already were long-lived given the definition that now excludes those patients (IDH-Mutant) with the best prognosis to live much longer. That definition was not pending when Optune ran its trial and got approved.
I'm sure someone has the stats on that already, if they exist, though again, they may not given that Optune's trial was short, accelerated and the IDH distinction was not a key differentiator at the time, I believe, in those trials.
Market Data 
Markets 
